BioCentury | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BioCentury | Oct 5, 2018
Financial News

Minoryx raises €21M series B, advances MIN-102

Minoryx Therapeutics S.L. (Mataro, Spain) raised €21.3 million ($24.7 million) on Sept. 26 in a series B round led by Fund+. SFPI, S.R.I.W. and Sambrinvest also participated as did existing investors Ysios Capital, Kurma Partners,...
BioCentury | Jul 17, 2018
Product R&D

Natural spots

With a new take on allosteric modulation, HotSpot Therapeutics Inc. has emerged from stealth mode to find specialized niches on proteins that nature uses to control their activity. The company’s platform has identified druggable allosteric...
BioCentury | Apr 12, 2017
Clinical News

MIN-102: Ph I data

A double-blind, placebo-controlled, Dutch Phase I trial in healthy male volunteers showed that single and multiple ascending doses of MIN-102 were generally well tolerated with no serious adverse events reported. Minoryx plans to start a...
BioCentury | Oct 24, 2016
Finance

Eyes on Spain

Ysios Capital Partners kept the doors open for its second fund longer than expected to welcome a new crop of deep-pocketed LPs who took interest in the firm’s latest investments. Ysios BioFund II Innvierte launched...
BioCentury | Oct 18, 2016
Financial News

Ysios closes EUR 126.4M fund

Spanish venture firm Ysios Capital Partners closed its second fund, Ysios BioFund II Innvierte, with EUR 126.4 million ($138.7 million). The raise was above its EUR 100 million ($109.8 million) target (see BioCentury Extra, March...
BioCentury | Aug 15, 2016
Clinical News

MIN-102: Phase I started

Minoryx began a double-blind, placebo-controlled, Dutch Phase I trial to evaluate single and multiple ascending doses of MIN-102 in healthy volunteers. Minoryx Therapeutics S.L. , Mataro, Spain Product: MIN-102 Business: Neurology Molecular target: Peroxisome proliferation activated...
BioCentury | Oct 19, 2015
Financial News

Minoryx completes venture financing

Minoryx Therapeutics S.L. , Mataro, Spain Business: Endocrine/Metabolic, Neurology Date completed: 2010-10-14 Type: Venture financing Raised: EUR19.4 million ($22.1 million) Investors: Ysios Capital Partners; Kurma Partners; Roche Venture Fund; Idinvest Partners; Chiesi Ventures; Caixa Capital WIR...
BioCentury | Oct 19, 2015
Finance

From Actos to act two

The improved properties of Minoryx Therapeutics S.L .'s backup PPAR gamma agonist versus lead molecule pioglitazone were enough to convince Ysios Capital to lead the rare disease company's €19.4 million ($22.1 million) series A round....
BioCentury | Oct 15, 2015
Financial News

Minoryx raises EUR 19.4 million

Minoryx Therapeutics S.L. (Barcelona, Spain) raised EUR 19.4 million ($22.1 million) in a series A round led by Ysios Capital. New investors Kurma Partners; Roche Venture Fund; Idinvest Partners; and Chiesi Ventures joined existing investors...
Items per page:
1 - 10 of 11
BioCentury | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BioCentury | Oct 5, 2018
Financial News

Minoryx raises €21M series B, advances MIN-102

Minoryx Therapeutics S.L. (Mataro, Spain) raised €21.3 million ($24.7 million) on Sept. 26 in a series B round led by Fund+. SFPI, S.R.I.W. and Sambrinvest also participated as did existing investors Ysios Capital, Kurma Partners,...
BioCentury | Jul 17, 2018
Product R&D

Natural spots

With a new take on allosteric modulation, HotSpot Therapeutics Inc. has emerged from stealth mode to find specialized niches on proteins that nature uses to control their activity. The company’s platform has identified druggable allosteric...
BioCentury | Apr 12, 2017
Clinical News

MIN-102: Ph I data

A double-blind, placebo-controlled, Dutch Phase I trial in healthy male volunteers showed that single and multiple ascending doses of MIN-102 were generally well tolerated with no serious adverse events reported. Minoryx plans to start a...
BioCentury | Oct 24, 2016
Finance

Eyes on Spain

Ysios Capital Partners kept the doors open for its second fund longer than expected to welcome a new crop of deep-pocketed LPs who took interest in the firm’s latest investments. Ysios BioFund II Innvierte launched...
BioCentury | Oct 18, 2016
Financial News

Ysios closes EUR 126.4M fund

Spanish venture firm Ysios Capital Partners closed its second fund, Ysios BioFund II Innvierte, with EUR 126.4 million ($138.7 million). The raise was above its EUR 100 million ($109.8 million) target (see BioCentury Extra, March...
BioCentury | Aug 15, 2016
Clinical News

MIN-102: Phase I started

Minoryx began a double-blind, placebo-controlled, Dutch Phase I trial to evaluate single and multiple ascending doses of MIN-102 in healthy volunteers. Minoryx Therapeutics S.L. , Mataro, Spain Product: MIN-102 Business: Neurology Molecular target: Peroxisome proliferation activated...
BioCentury | Oct 19, 2015
Financial News

Minoryx completes venture financing

Minoryx Therapeutics S.L. , Mataro, Spain Business: Endocrine/Metabolic, Neurology Date completed: 2010-10-14 Type: Venture financing Raised: EUR19.4 million ($22.1 million) Investors: Ysios Capital Partners; Kurma Partners; Roche Venture Fund; Idinvest Partners; Chiesi Ventures; Caixa Capital WIR...
BioCentury | Oct 19, 2015
Finance

From Actos to act two

The improved properties of Minoryx Therapeutics S.L .'s backup PPAR gamma agonist versus lead molecule pioglitazone were enough to convince Ysios Capital to lead the rare disease company's €19.4 million ($22.1 million) series A round....
BioCentury | Oct 15, 2015
Financial News

Minoryx raises EUR 19.4 million

Minoryx Therapeutics S.L. (Barcelona, Spain) raised EUR 19.4 million ($22.1 million) in a series A round led by Ysios Capital. New investors Kurma Partners; Roche Venture Fund; Idinvest Partners; and Chiesi Ventures joined existing investors...
Items per page:
1 - 10 of 11